天士力 20250428 摘要 • 天士力融入华润后，正制定十五战略规划，明确自身在华润三九"一体两 翼"模式下的定位和业务发展目标，并积极与华润系各业务单元对接，落 地协同项目，旨在巩固核心业务并拓展新的增长点。 • 2025 年一季度，天士力克服复方丹参滴丸降价压力，实现营收 20.55 亿 元，医药工业主营业务收入 18.42 亿元，同比增长 1.83%；归母净利润 3.14 亿元，同比增长 6.47%，资产负债率维持在 19%的较低水平，整体 经营稳健。 • 复方丹参滴丸虽面临降价压力，但销量和销售收入保持稳定，且新适应症 （如糖尿病视网膜病变）市场潜力巨大，公司正加大推广力度，全年预计 呈现前低后高的增长态势。 • 公司预计 2025 年中药板块保持稳定增长，得益于三大基药品种在基层市 场的推广以及扫码纸巾颗粒和牛黄清心丸等潜力品种的快速增长，其中养 血清脑颗粒在抽动症治疗领域具有独特优势。 • 化学药板块坚持仿创结合，水林佳和地清两大主力产品保持稳定增长，同 时预计 2025 年将有 3 个仿制药新品获批，6 个产品申报，持续提供市场 增量。 Q&A 2025 年公司在中药、化药及生物药三个板块的 ...

姑苏烟雨里，一场创意与诗意的相逢 当春日的湿气浸润粉墙黛瓦，天士力藿香正气滴丸联合学院奖的创意列车，载着中药创新药的智慧与青春的炽热灵感，驶入江南 文化腹地——苏州大学。3月26日，独墅湖畔的炳麟图书馆报告厅内，传统与现代、诗情与科技交织，一场关于健康守护与创意 落地的对话，在吴侬软语的温柔底色中热烈展开。 游园惊创：苏式美学里的祛湿灵感场 春风拂面，花开正艳。宜人的校园内，师生聚集，是去赏花吗？不是，原来都争先恐后地参与品牌展区的互动游戏。天士力藿香 正气滴丸搭建的"祛湿能量站"好似命运安排的健康守护大侠，为即将迎来湿暑天气的苏韵江南打开祛湿防暑新局面。 姑苏城的这场对话，既让健康理念随着欢笑声潜入日常，也让品牌与青春共鸣的诚意，如春日的吴江细浪，温柔却坚定地漫向远 方。 养天地正气，法古今完人。从户外步入室内，泥土的气息渐渐被油墨的芳香晕染，炳麟图书馆报告厅内呈现出别样景象。天士力 藿香正气滴丸的巨大药盒吸引众多师生驻足围观，命题策略单也大受欢迎，被同学们翻看讨论。 天士力医药集团公关与整合传播负责人刘珊女士用一场深入浅出的演讲，将"中药创新药"的品牌定位与青年创意反复碰撞，为苏 大师生搭建起了灵感桥梁， ...

Core Viewpoint - Pianzaihuang's acquisition of "Wenfei Dingchuan Granules" marks its entry into the respiratory market, with potential for becoming the first approved proprietary traditional Chinese medicine (TCM) in this field, indicating a significant market opportunity [1][2] Group 1: Acquisition Details - Pianzaihuang acquired all rights to the TCM "Wenfei Dingchuan Granules" for 13.58 million yuan, aiming to expand into the treatment of chronic obstructive pulmonary disease (COPD) [1][2] - The granules are designed to treat lung and kidney qi deficiency and phlegm obstruction in stable COPD patients, with no similar TCM products currently approved in China [2] Group 2: Market Potential and Challenges - The global burden of COPD results in over 3 million deaths annually, with predictions indicating that by 2030, China will see 1.0554 million deaths from COPD due to aging, smoking, and air pollution [2] - Despite the promising market outlook, Pianzaihuang faces intense competition from chemical and biological drugs in the COPD treatment space, necessitating proof of differentiated value for its TCM innovation [2][3] Group 3: R&D Investment Concerns - Pianzaihuang's R&D investment has decreased, with a 19.59% year-on-year decline in the first three quarters of 2024, raising concerns about its ability to sustain long-term innovation [1][6] - The company’s R&D expenses for the first half of 2024 were 116 million yuan, a slight decrease from previous years, positioning it lower than peers like Baiyunshan and Yiling [6] Group 4: Industry Trends and Future Outlook - The TCM innovation sector has seen a rise in IND applications, with a compound annual growth rate of 62.66% from 2020 to 2024, indicating a growing interest in TCM new drug development [7] - Pianzaihuang has invested nearly 500 million yuan in various health funds since 2024, suggesting a strategic shift towards integrating its operations within the broader health industry [8][9] - The company is also exploring acquisitions to enhance its growth potential, although some transactions have faced scrutiny regarding their strategic value [10]